menu
    • menu
    [{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MediLink Therapeutics","amount2":1.0700000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.0700000000000001,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"MediLink Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":1,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Tarlatamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"14","companyTruncated":"MediLink Therapeutics \/ Amgen Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by MediLink Therapeutics

    Menu

    MediLink Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MediLink Therapeutics

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MediLink Therapeutics

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YL201,Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Amgen Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MediLink And YL201 Collaborate on Global Clinical Trial And Supply Agreement

                            Details : Amgen will lead a global clinical study to evaluate the potential of the combination of MediLink's B7-H3-targeting ADC YL201 and Amgen's DLL3- and CD3-targeting BiTE® IMDELLTRA™ in ES-SCLC.

                            Brand Name : YL201

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : YL201,Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Amgen Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MediLink Therapeutics

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MediLink Therapeutics

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YL211

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MediLink Announces Collaboration with Roche for Antibody Drug Conjugate

                            Details : Under the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of YL211, an antibody-drug conjugate for solid tumors.

                            Brand Name : YL211

                            Molecule Type : Large molecule

                            Upfront Cash : $50.0 million

                            January 02, 2024

                            Lead Product(s) : YL211

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MediLink Therapeutics

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MediLink Therapeutics

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BioNTech

                            Deal Size : $1,070.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to Devel...

                            Details : Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets, against Human Epidermal Growth Factor Receptor 3 (HER3).

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $70.0 million

                            October 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BioNTech

                            Deal Size : $1,070.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth